Buy or sell QED Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

QED Therapeutics Stock

A biotechnology company focused on precision medicine for FGFR-driven disorders.

Headquarters

Palo Alto CA, US

Total Funding

$65.0M

About QED Therapeutics Stock

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.

Funding History

January 2018$65.0M

Management

President

Neil Kumar

CRO

Curtis Scribner

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from QED Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo